颈动脉支架置入后行冠状动脉旁路移植术的30天结局:系统综述与荟萃分析
该系统综述纳入31项研究、2727例颈动脉与心脏并存疾病患者,多数为无症状单侧颈动脉狭窄。汇总30天死亡/卒中率为7.9%(95%CI 6.9-9.2),死亡/卒中/心肌梗死为8.8%(95%CI 7.3-10.5);分期CAS+CABG的30天死亡/卒中率为8.5%(95%CI 7.3-9.7),同日手术为5.9%(95%CI 4.0-8.5),有神经系统症状者结局更差。
要点
- 汇总30天死亡/卒中率约8%,死亡/卒中/心梗率8.8%
- 分期与同日CAS+CABG的30天死亡/卒中率分别为8.5%与5.9%
- 有神经系统症状者操作相关卒中率达15%
核心结论
- 在主要为无症状单侧颈动脉狭窄患者中,CAS后行CABG的30天死亡/卒中率约为8%。
- 尽管存在潜在偏倚,本荟萃分析未发现同日CAS+CABG的结局高于分期干预的证据。
- 神经系统症状患者的结局更差,仍需更多数据确定最佳抗血小板策略。
研究设计与样本
- 系统综述,检索PubMed/Medline、Embase和Cochrane数据库。
- 纳入31项符合条件的研究,共2727例患者。
- 80%患者为神经系统无症状的单侧狭窄;同日指CAS与CABG同一天完成,分期指两者间隔至少1天。
主要发现
- 总体30天死亡/卒中率为7.9%(95%CI 6.9-9.2)。
- 总体30天死亡/卒中/心肌梗死率为8.8%(95%CI 7.3-10.5)。
- 分期CAS+CABG的30天死亡/卒中率为8.5%(95%CI 7.3-9.7),同日手术为5.9%(95%CI 4.0-8.5)。
- 有神经系统症状者操作相关卒中率为15%。
关键数值与推荐
- 抗血小板策略(a)无抗血小板治疗:死亡/卒中/心梗4.2%,无出血并发症数据。
- 策略(b)CAS前单联、CABG后双联:死亡/卒中/心梗6.7%,出血并发症7.3%。
- 策略(c)CAS前双联、CABG前降为单联:死亡/卒中/心梗10.1%,出血并发症2.8%。
- 策略(d)CAS前双联、CABG前两者均停:死亡/卒中/心梗14.4%。
- 策略(e)CAS前双联并持续至CABG:死亡/卒中/心梗16%;后两种策略出血并发症数据不足。
临床怎么用
- 对合并颈动脉与冠心病的患者,CAS+CABG围术期应重点关注30天死亡/卒中风险,约8%。
- 同日与分期CAS+CABG的选择可结合患者情况个体化,本分析未显示同日结局更差。
- 有神经系统症状者操作相关卒中风险达15%,术前评估与沟通需更谨慎。
- 抗血小板策略与缺血/出血结局相关,但现有数据不足以确立最优方案。
局限性
- 存在潜在偏倚,影响同日与分期比较的解释。
- 多数患者为无症状单侧狭窄,结论外推至症状性或其他狭窄类型受限。
- 最后两种抗血小板策略的出血并发症数据不足,无法充分评估最优抗血小板方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim was to determine 30-day outcomes in patients with concurrent carotid and cardiac disease who underwent carotid artery stenting (CAS) followed by coronary artery bypass grafting (CABG). METHODS: This was a systematic review with searches of PubMed/Medline, Embase, and Cochrane databases. "Same-day" procedures involved CAS + CABG being performed on the same day, and "staged" interventions involved at least 1 day's delay between undergoing CAS and then CABG. RESULTS: There were 31 eligible studies (2727 patients), with 80% being neurologically asymptomatic with unilateral stenoses. Overall, the 30-day death/stroke rate was 7.9% (95% confidence interval [CI] 6.9-9.2), while death/stroke/MI was 8.8% (95% CI 7.3-10.5). Staged CAS + CABG was associated with 30-day death/stroke rate of 8.5% (95% CI 7.3-9.7) compared with 5.9% (95% CI 4.0-8.5) after "same-day" procedures. Outcomes following CAS + CABG in neurologically symptomatic patients were poorer, with procedural stroke rates of 15%. There were five antiplatelet (APRx) strategies: (a) no APRx (death/stroke/MI, 4.2%; no data on bleeding complications); (b) single APRx before CAS and CABG, then dual APRx after CABG (death/stroke/MI, 6.7%; 7.3% bleeding complications); (c) dual APRx pre-CAS down to one APRx pre-CABG (death/stroke/MI, 10.1%; 2.8% bleeding complications); (d) dual APRx pre-CAS, both stopped pre-CABG (death/stroke/MI, 14.4%); (e) dual APRx pre-CAS and continued through CABG (death/stroke/MI, 16%). There were insufficient data on bleeding complication in the last two strategies. CONCLUSIONS: In a cohort of predominantly asymptomatic patients with unilateral carotid stenoses, the 30-day rate of death/stroke was about 8%. Notwithstanding the effect of potential biases, this meta-analysis did not find evidence that outcomes after same-day CAS + CABG were higher than after staged interventions. However, outcomes were poorer in neurologically symptomatic patients. More data are required to establish the optimal antiplatelet strategy in patients undergoing same-day or staged CAS + CABG.
引用
- Paraskevas KI, Nduwayo S, Saratzis AN, et al. Carotid Stenting Prior to Coronary Bypass Surgery: An Updated Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2017. PMID: 28094166. doi:10.1016/j.ejvs.2016.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。